Investment
Features
FeesSafety
Academy
More
Pluang+

Compare 8x8 Inc (EGHT) vs Smith & Nephew plc (SNN) Price & Performance

8x8 IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

8x8 Inc vs Smith & Nephew plc — how do they compare? 8x8 Inc trades at $1.93 (market cap $279.31M), while Smith & Nephew plc trades at $31.3 (market cap $12.81B). The key difference: Smith & Nephew plc is far larger — about 45.9× 8x8 Inc's market cap, and Smith & Nephew plc pays a 2.54% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals.

EGHTSNN
Market Cap
$279.31M$12.81B
Sector
TechnologyHealth
52-Week High
$2.76$38.70
52-Week Low
$1.59$28.73
Enterprise Value
$556.99M$15.58B
Dividend Yield
2.54%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

8x8 Inc

EGHT (8x8, Inc.) trades at $1.89, down 12.9% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $27.21M in 2025 despite revenue of $715.07M, though recent quarters have beaten EPS estimates. Positive news includes AI product launches and industry awards, while analyst consensus is mixed with 39% buy ratings.

Outlook hinges on profitability improvement; projected net income of $2M in 2026 offers potential upside, but high debt and thin margins pose risks. Stock sentiment is cautiously optimistic due to innovation, yet volatility and competitive pressures require monitoring for sustained growth.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $29.83, down 4.02% today, with a bearish technical signal. The company reported revenue of $5.81 billion in 2024, with net income of $412 million, showing improved profitability. Recent news highlights product launches in robotics and wound care, supported by a $500 million share buyback. Analyst consensus is mixed, with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility.

Outlook is balanced: strong free cash flow and innovation in medical technology offer growth potential, but near-term risks include competitive pressures and debt levels. The stock's valuation at a P/E of 21.51 is reasonable if earnings growth sustains, yet technical weakness suggests caution. Investors should weigh solid fundamentals against market sentiment and execution risks.

Returns comparison

Trailing returns across standard periods

About 8x8 Inc

8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.

Read more on EGHT

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN